Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.

The antibody–drug conjugate trastuzumab deruxtecan induces a high intracranial response rate among women with HER2-positive breast cancer and active brain metastases, TUXEDO-1 study findings indicate.

medwireNews : The antibody–drug conjugate fam-trastuzumab deruxtecan-nxki has received regular approval from the US FDA for the treatment of HER2-positive advanced breast cancer.

Women with estrogen receptor-low positive breast cancer may be considered for 2 to 3 years of endocrine therapy rather than the standard 5 years without a negative impact on disease-free survival, Chinese researchers report.

The second-generation irreversible pan-HER tyrosine kinase inhibitor pyrotinib in combination with capecitabine shows promising activity against brain metastases in women with HER2-positive metastatic breast cancer, say researchers.

A phase 3 trial has demonstrated a significant progression-free survival benefit with the oral SERD elacestrant relative to standard of care in pretreated patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

Adjuvant treatment with metformin does not improve the outcomes of patients with HR-positive or negative early breast cancer, suggest trial data presented at the 2021 San Antonio Breast Cancer Symposium.

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from the novel HER2-targeted antibody–drug conjugate trastuzumab duocarmazine relative to standard treatment, shows the TULIP trial.

Objective To analyze the onset of adverse drug reactions (ADRs) related to the use of HER2-positive breast cancer treatments through a spontaneous reporting system (SRS) database.

Neoadjuvant treatment with trastuzumab emtansine is associated with similar pathologic complete response rates as the combination of docetaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer, study findings indicate.

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

Treatment with the novel HER2-targeted agent margetuximab improves the outcomes of heavily pretreated patients with HER2-positive advanced breast cancer, indicate phase 3 trial results.

Breast cancer decisions The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for use of trastuzumab deruxtecan as a third- or later-line treatment for patients with unresectable or metastatic HER2-positive breast cancer.

Ruth O'Regan comments on the monarchE trial of abemaciclib and the PENELOPE-B and PALLAS trials of palbociclib investigating CDK4/6 inhibitor therapy in the adjuvant, hormone receptor-positive, early-stage breast cancer setting (6:35).

Pathologic complete response is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.

The addition of enzalutamide to exemestane may improve the progression-free survival of a subset of patients with HR-positive, HER2-negative, advanced breast cancer, study data suggest.

The addition of CDK4/6 inhibitors to endocrine therapy is associated with improved outcomes in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, shows a meta-analysis.